Integrated Single-Cell Profiling Reveals TL1A as a Biomarker and Driver of Type 2 Inflammation via Macrophage-Dependent Immunoregulation in Asthma - PubMed
3 hours ago
- #Immunoregulation
- #Asthma
- #Biomarker
- TL1A levels are elevated in asthma patients and correlate with disease severity, lung function decline, and eosinophil counts.
- Macrophages are identified as the primary expressors of TL1A in allergic lung inflammation.
- Knockout of TL1A in macrophages attenuates airway inflammation and type 2 cytokine secretion.
- TL1A drives type 2 inflammation by inducing CCL8 expression via death receptor 3 activation.
- Anti-TL1A antibody interventions suppress type 2 responses and reduce pathogenic CD8+ T cells in a dose-dependent manner.
- TL1A serves as both a biomarker and therapeutic target, modulating macrophage-driven asthma pathogenesis.